Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 juil. 2024 13h00 HE | Source: DelveInsight Business Research LLP

Metastatic Prostate Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight

New York, USA, July 10, 2024 (GLOBE NEWSWIRE) -- Metastatic Prostate Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight The metastatic prostate cancer market is driven...
19 janv. 2023 07h30 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium

HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
06 déc. 2021 07h30 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market

- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in...
28 janv. 2021 16h05 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the...